Atomwise

Atomwise

Atomwise is a company that develops AI solutions for drug discovery.

Atomwise is an AI-based drug discovery company headquartered in San Francisco, California. Atomwise was founded in 2012 and was formerly known as Chematria.

In January 2019, Charles River Laboratories and Atomwise formed an alliance to provide integrated, AI-Driven drug discovery.

History and Approach

Atomwise’s technology was first developed by Dr. Wallach, a PhD student at the University of Toronto. The technology uses convolutional neural networks to predict the bioactivity of small molecules for drug discovery applications. It uses a statistical approach that extracts insights from experimental affinity measurements and protein structures to predict the binding of small molecules to proteins.

This tool allows chemists to pursue hit discovery, lead optimization and toxicity predictions. Atomwise analyzes billions of compounds to identify a small, specific subset for synthesis and testing.

AtomNet

AtomNet is Atomwise's deep convolutional network.

AtomNet represents a protein-ligand pair as a set of 3-dimensional volumetric pixels containing channels for carbon, oxygen, nitrogen, etc atom types. AtomNet applies local convolutional filters to structural target information to predict new active molecules for targets with no previously known modulators.

Timeline

September 12, 2019

Atomwise Announces Largest China-US Collaboration for AI Drug Discovery

Atomwise announced a collaboration with Hansoh Pharmaceutical Group Company Limited, a biopharmaceutical company in China, to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas.

September 12, 2019

Atomwise signs four new deals for AI-based drug discovery

April 16, 2019

Atomwise and DNDi collaborate to advance drug development using AI for neglected diseases.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Atomwise funding round, June 2015
Seed round
6,000,000
June 3, 2015
Draper Associates
Atomwise Inc funding round, March 2018
Series A round
45,000,000
March 2018
Y Combinator
Atomwise Funding Round 2018
Series A round
45,000,000
March 7, 2018
Atomwise Inc. funding round, August 2020
126,999,992
August 2020
Atomwise funding round, March 2015
Seed round
120,000
March 23, 2015
Y Combinator
Atomwise funding round, January 2013
225,000
January 1, 2013
6 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Abraham Heifets

Founder

Alexander Levy

Founder

David E. Weekly

Investor

David Lee

Investor

Izhar Wallach

Founder

Jasna Delic

Employee

Jeff Chung

Investor

Jeff Huber

Investor

Mohammad Islam

Investor

Stefano Bernardi

Investor

Stephanie Rosenbloom

Employee

Further reading

Title
Author
Link
Type
Date

Atomwise- News and Publications

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Jonathan Shieber
August 11, 2020
TechCrunch
With a slew of partnerships with large pharmaceutical companies under its belt and the successful spin out of at least one new company, Atomwise has already proved the value of its machine learning platform for discovering and commercializing potential small molecule therapies for a host of conditions. Now the company has raised $123 million in [...]
BioSpace
May 21, 2020
BioSpace
Atomwise democratizes access to its advanced AI technology with 15 research collaborations underway to enable academic researchers to discover novel therapies for this pandemic and those in the future.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.